BerGenBio: Preclinical data presented at AACR reinforces bemcentinib’s potential to reverse tumour immunosuppression and therapy resistance

· Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL’s role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR · Selective AXL inhibitor, bemcentinib, shown to reverse AXL’s effects, thus acting synergistically with immune cells and anti-cancer therapies · Data further strengthens broad development opportunities for bemcentinib both as a monotherapy, and in combinations, in a broad spectrum of cancersBergen, Norway, 2 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage